Company: MDCXW
Filing Date: 2025-11-19
Form Type: S-1
Source: 0001062993-25-016962
Chunk: 250

Company: Medicus Pharma Ltd.
Filing Date: 2025-11-19
Form: S-1
Chunk 250
---
-of-use assets       | $ |           196,249 |     | $ |      268,571 |
| Operating lease liabilities - current     |   |           141,070 |     |   |      116,323 |
| Operating lease liabilities - non-current |   |            95,188 |     |   |      205,945 |

Other information related to leases is presented below:

| Lease cost                                    |   | Nine Months Ended 
     September 30, 
              2025 |     |   | Nine Months Ended 
     September 30, 
              2024 |
|:----------------------------------------------|:--|------------------:|:----|:--|------------------:|
| Operating lease cost                          | $ |            92,483 |     | $ |            92,483 |
| Other information                             |   |                   |     |   |                   |
| Operating cash flows used in operating leases |   |           106,171 |     |   |            35,040 |
| Remaining lease term (in years)               |   |              1.75 |     |   |              2.75 |
| Discount rate                                 |   |               10% |     |   |               10% |

<div align='center'>F-34</div>

As of September 30, 2025, the annual future minimum lease payments of the Company's operating lease liabilities were as follows:

| 2025                                              | $ | 145,448 |   |
| 2026                                              |   | 111,522 |   |
| Total future minimum lease payments, undiscounted |   | 256,969 |   |
| Present value discount                            |   | (20,711 | ) |
| Total lease liability                             | $ | 236,258 |   |

5. Share capital

Authorized

The Company has authorized an unlimited number of common shares participating, voting and without par value. Each holder of common shares is entitled to one vote for each share owned on all matters voted upon by shareholders.

On October 28, 2024, the Company completed a reverse share split at the ratio of 1-for-2, resulting in 10,846,721 common shares after conversion.

Conversion of convertible notes

On May 3, 2024, the Company issued convertible notes in the principal amount of $5,172,500. The convertible notes accrued interest at the rate of 10% per annum,